Tag Archives: Bellerophon

Maxim Group Thinks Bellerophon’s Stock is Going to Recover

In a report released today, Caroline Palomeque from Maxim Group initiated coverage with a Buy rating on Bellerophon (BLPH – Research Report) and a price target of $3. The company’s shares closed yesterday at $0.67, close to its 52-week low

H.C. Wainwright Thinks Bellerophon’s Stock is Going to Recover

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Bellerophon (NASDAQ: BLPH), with a price target of $3. The company’s shares closed yesterday at $0.60, close to its 52-week low of $0.47. Fein commented:

H.C. Wainwright Maintains Their Buy Rating on Bellerophon (BLPH)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Bellerophon (NASDAQ: BLPH), with a price target of $5. The company’s shares closed yesterday at $2.53. Fein wrote: “Valuation and risks. Our price target of

Analysts Offer Insights on Healthcare Companies: Bellerophon (NASDAQ: BLPH), Spero Therapeutics Inc (NASDAQ: SPRO) and Mirati Therapeutics (NASDAQ: MRTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bellerophon (NASDAQ: BLPH), Spero Therapeutics Inc (NASDAQ: SPRO) and Mirati Therapeutics (NASDAQ: MRTX) with bullish sentiments. Bellerophon (NASDAQ: BLPH) In a report

Analysts Offer Insights on Healthcare Companies: Bellerophon (NASDAQ: BLPH) and Pluristem (NASDAQ: PSTI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bellerophon (NASDAQ: BLPH) and Pluristem (NASDAQ: PSTI) with bullish sentiments. Bellerophon (NASDAQ: BLPH) In a report released today, Andrew Fein from H.C.

Analysts Are Bullish on These Healthcare Stocks: BLPH, CALA

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bellerophon (NASDAQ: BLPH) and Calithera Bio (NASDAQ: CALA) with bullish sentiments. Bellerophon (NASDAQ: BLPH) H.C. Wainwright analyst Andrew Fein reiterated a Buy